Mind and machine in drug design

After a difficult start, medicinal chemists are now ready to embrace AI-based methods and concepts in drug discovery, explains Gisbert Schneider.

[1]  J. Zupan,et al.  Neural Networks in Chemistry , 1993 .

[2]  W Patrick Walters,et al.  What do medicinal chemists actually make? A 50-year retrospective. , 2011, Journal of medicinal chemistry.

[3]  Petra Schneider,et al.  Generative Recurrent Networks for De Novo Drug Design , 2017, Molecular informatics.

[4]  Ken Goldberg,et al.  Robots and the return to collaborative intelligence , 2019, Nature Machine Intelligence.

[5]  Anthony Wood,et al.  Organic synthesis provides opportunities to transform drug discovery , 2018, Nature Chemistry.

[6]  J S Smith,et al.  ANI-1: an extensible neural network potential with DFT accuracy at force field computational cost , 2016, Chemical science.

[7]  S. Graubard,et al.  The artificial intelligence debate: false starts, real foundations , 1990 .

[8]  Alexandre Tkatchenko,et al.  Quantum-chemical insights from deep tensor neural networks , 2016, Nature Communications.

[9]  João Rodrigues,et al.  Why and how have drug discovery strategies in pharma changed? What are the new mindsets? , 2016, Drug discovery today.

[10]  Gisbert Schneider,et al.  Generative Models for Artificially‐intelligent Molecular Design , 2018, Molecular informatics.

[11]  J. Scannell,et al.  Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.

[12]  Allan M Jordan,et al.  Artificial Intelligence in Drug Design-The Storm Before the Calm? , 2018, ACS medicinal chemistry letters.

[13]  Petra Schneider,et al.  De Novo Design at the Edge of Chaos. , 2016, Journal of medicinal chemistry.

[14]  G Schneider,et al.  Structure optimization of an artificial neural filter detecting membrane-spanning amino acid sequences. , 1996, Biopolymers.

[15]  Gisbert Schneider,et al.  De Novo Design of Bioactive Small Molecules by Artificial Intelligence , 2018, Molecular informatics.

[16]  Connor W. Coley,et al.  Machine Learning in Computer-Aided Synthesis Planning. , 2018, Accounts of chemical research.

[17]  Ken E. Whelan,et al.  The Automation of Science , 2009, Science.

[18]  Eric J Topol,et al.  High-performance medicine: the convergence of human and artificial intelligence , 2019, Nature Medicine.

[19]  V. Seifert.  An alternative approach to unifying chemistry with quantum mechanics , 2017 .

[20]  K. Śmietana,et al.  Trends in clinical success rates , 2016, Nature Reviews Drug Discovery.

[21]  R. A. Thompson,et al.  Hypothesis driven drug design: improving quality and effectiveness of the design-make-test-analyse cycle. , 2012, Drug discovery today.

[22]  V. Lee.  Personalized medicine: transforming drug development and healthcare. , 2010, Therapeutic delivery.

[23]  Tanmoy Bhattacharya,et al.  The need for uncertainty quantification in machine-assisted medical decision making , 2019, Nat. Mach. Intell..

[24]  G. Hessler,et al.  Artificial Intelligence in Drug Design , 2018, Molecules.

[25]  Thomas H. Pierce,et al.  Artificial intelligence applications in chemistry , 1986 .

[26]  Gisbert Schneider,et al.  Tuning artificial intelligence on the de novo design of natural-product-inspired retinoid X receptor modulators , 2018, Communications Chemistry.

[27]  Katharine Sanderson.  March of the synthesis machines , 2015, Nature Reviews Drug Discovery.

[28]  Kit-Kay Mak,et al.  Artificial intelligence in drug development: present status and future prospects. , 2019, Drug discovery today.

[29]  G Schneider,et al.  Artificial neural networks for computer-based molecular design. , 1998, Progress in biophysics and molecular biology.

[30]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[31]  Gisbert Schneider,et al.  Automating drug discovery , 2017, Nature Reviews Drug Discovery.

[32]  Mike Preuss,et al.  Planning chemical syntheses with deep neural networks and symbolic AI , 2017, Nature.